WATKINS FRANK T 4
4 · Shockwave Medical, Inc. · Filed Nov 21, 2023
Insider Transaction Report
Form 4
WATKINS FRANK T
Director
Transactions
- Exercise/Conversion
Common Stock
2023-11-20$3.42/sh+3,000$10,248→ 4,532 total - Sale
Common Stock
2023-11-20$174.22/sh−1,205$209,935→ 1,532 total - Sale
Common Stock
2023-11-20$171.75/sh−664$114,042→ 3,868 total - Exercise/Conversion
Stock Option
2023-11-20−3,000→ 93,313 totalExercise: $3.42Exp: 2027-05-09→ Common Stock (3,000 underlying) - Sale
Common Stock
2023-11-20$173.36/sh−1,131$196,070→ 2,737 total
Footnotes (5)
- [F1]All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 12/7/2022.
- [F2]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $171.63 to $172.32. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F3]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $172.72 to $173.67. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F4]The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $173.83 to $174.46. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- [F5]Twenty-Five percent of the shares subject to the option vested on 2/25/18 and the balance of the shares vested in equal monthly installments thereafter for 36 months.